196 related articles for article (PubMed ID: 3533722)
1. [Study of promutagen biotransformation in the Ames test. III. The role of conjugation with glucuronic acid and sulfate in the modification of mutagenic effect of nitrosomorpholine, diethylnitrosamine and cyclophosphamide].
Loknitskaia NN; Rotenberg IuS; Fonshteĭn LM; Shuliakovskaia TS
Genetika; 1986 Sep; 22(9):2259-64. PubMed ID: 3533722
[TBL] [Abstract][Full Text] [Related]
2. [Study of the process of promutagen biotransformation by the Ames test. I. The role of conjugation with glutathione in the modification of the mutagenic activity of nitrosomorpholine, diethylnitrosamine and cyclophosphamide].
Fonshteĭn LM; Loknitskaia NN; Rotenberg IuS
Genetika; 1985 Nov; 21(11):1821-7. PubMed ID: 3908219
[TBL] [Abstract][Full Text] [Related]
3. [The process of promutagen biotransformation studied by the Ames test. II. The extent of the manifestation of the mutagenic action of nitrosomorpholine, diethylnitrosamine and cyclophosphane using various subfractions of rat liver homogenate].
Loknitskaia NN; Fonshteĭn LM
Genetika; 1985 Dec; 21(12):1932-6. PubMed ID: 4085789
[TBL] [Abstract][Full Text] [Related]
4. [Butylhydroxytoluene inhibition of the mutagenic activity of carcinogenic nitroso compounds and cyclophosphamide: the role of the glutathione conjugation reaction].
Kalinina EV; Loknitskaia NN; Shuliakovskaia TS; Fonshteĭn LM
Vopr Onkol; 1987; 33(9):59-63. PubMed ID: 3310399
[TBL] [Abstract][Full Text] [Related]
5. [Study of promutagen biotransformation in the Ames test. IV. The effect of transplanted tumors on the biotransformation of various antineoplastic agents].
Oblapenko NG; Loknitskaia NN; Presnova ZhF; Chernov VA; Fonshteĭn LM
Genetika; 1986 Sep; 22(9):2265-71. PubMed ID: 3533723
[TBL] [Abstract][Full Text] [Related]
6. [Study of the biotransformation of various antineoplastic agents using the Ames test].
Oblapenko NG; Prikhod'ko AZ; Fonshteĭn LM; Chernov VA
Eksp Onkol; 1988; 10(5):52-5. PubMed ID: 3061779
[TBL] [Abstract][Full Text] [Related]
7. [The role of UDP glucuronosyl- and sulfotransferases in the butylhydroxytoluene suppression of the mutagenic action of carcinogenic nitroso compounds and cyclophosphane].
Kalinina EV; Loknitskaia NN; Shuliakovskaia TS; Fonshteĭn LM
Vopr Onkol; 1989; 35(2):220-5. PubMed ID: 2494809
[TBL] [Abstract][Full Text] [Related]
8. Mutagenicity of potassium alkanediazotates and their use as model compounds for activated nitrosamines.
Hecker LI; Saavedra JE; Farrelly JG; Andrews AW
Cancer Res; 1983 Sep; 43(9):4078-82. PubMed ID: 6347365
[TBL] [Abstract][Full Text] [Related]
9. [Modifying action of drug preparations on the effect of promutagen compounds].
Oblapenko NG; Fonshteĭn LM
Tsitol Genet; 1987; 21(2):118-22. PubMed ID: 3296365
[TBL] [Abstract][Full Text] [Related]
10. Salmonella/human S9 mutagenicity test: a collaborative study with 58 compounds.
Hakura A; Shimada H; Nakajima M; Sui H; Kitamoto S; Suzuki S; Satoh T
Mutagenesis; 2005 May; 20(3):217-28. PubMed ID: 15843387
[TBL] [Abstract][Full Text] [Related]
11. [Ames test study of the effect of 2nd-phase biotransformation reactions on the level of mutagenic action of a number of chemical compounds].
Loknitskaia NN; Fonshteĭn LM
Tsitol Genet; 1988; 22(3):43-6. PubMed ID: 3142125
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the metabolizing capacity of S9 liver preparations from rats and mice using a test with Salmonella typhimurium TA100.
Gajcy H; Pieńkowska K; Koziorowska J; Czarnomska A
Pol J Pharmacol Pharm; 1987; 39(1):27-32. PubMed ID: 3313326
[TBL] [Abstract][Full Text] [Related]
13. [Additional pathway of the metabolic activation of N-nitrosodiethylamine in the rat liver].
Khripach LV; Shuliakovskaia TS; Loknitskaia NN; Fonshteĭn LM
Eksp Onkol; 1987; 9(2):46-9. PubMed ID: 3582239
[TBL] [Abstract][Full Text] [Related]
14. Mutagenicity of some hydroxylaminotoluene derivatives towards Salmonella typhimurium in esterification systems.
Mori M; Sayama M; Futagami M; Naito M; Miyahara T; Kozuka H
J Pharmacobiodyn; 1986 Dec; 9(12):1036-9. PubMed ID: 3553529
[TBL] [Abstract][Full Text] [Related]
15. Modification of the mutagenicity and teratogenicity of cyclophosphamide in rats with inducers of the cytochromes P-450.
Hales BF
Teratology; 1981 Aug; 24(1):1-11. PubMed ID: 7029774
[TBL] [Abstract][Full Text] [Related]
16. Increased mutagenicity of chloroethylnitrosoureas in the presence of a rat liver S9 microsome mixture.
Suling WJ; Rice LS; Shannon WM
J Natl Cancer Inst; 1983 Apr; 70(4):767-9. PubMed ID: 6220173
[TBL] [Abstract][Full Text] [Related]
17. The mutagenicity of aflatoxin Q1 to Salmonella typhimurium TA 100 with or without rat or human liver microsomal preparations.
Yourtee DM; Kirk-Yourtee CL
Res Commun Chem Pathol Pharmacol; 1986 Oct; 54(1):101-13. PubMed ID: 3099349
[TBL] [Abstract][Full Text] [Related]
18. [Effect of modifiers of the cytochrome P-450-dependent enzyme system of the liver on the metabolic pathways of diethylnitrosamine activation and inactivation].
Shuliakovskaia TS; Koen IaM; Rykova VA; Loknitskaia NN; Fonshteĭn LM
Vopr Onkol; 1987; 33(1):78-83. PubMed ID: 3544492
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cyclophosphamide mutagenicity by beta-carotene.
Belisario MA; Pecce R; Battista C; Panza N; Pacilio G
Biomed Pharmacother; 1985; 39(8):445-8. PubMed ID: 3914914
[TBL] [Abstract][Full Text] [Related]
20. Metabolic activation capabilities of S9 and hepatocytes from uninduced rats to convert carcinogenic N-nitrosamines to mutagens.
Rumruen K; Pool BL
Mutat Res; 1984; 140(2-3):147-53. PubMed ID: 6379440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
